Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.

ABSTRACT: Lenvatinib is an oral multikinase inhibitor approved for use as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, like other agents in this drug class, lenvatinib is associated with clinically important adverse events (AEs) that could adversely affect patient outcomes. Hypertension, diarrhea, decreased appetite/weight, hand-foot skin reaction, and proteinuria are among the most common AEs associated with lenvatinib therapy. This article provides strategies for the effective management of lenvatinib-associated AEs based on the expert opinion of authors and currently available literature. Due to the high risk of AEs in patients receiving lenvatinib, prophylactic measures and regular monitoring for AEs are recommended. Lenvatinib dose interruption, adjus

SUBMITTER: Kim BH 

PROVIDER: S-EPMC9299126 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature